Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Export of Misfolded Proteins out of the ER

Export of Misfolded Proteins out of the ER

After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Zinc Differentially Modulates Tau Aggregation, Fibril Morphology, and Prion-like Seeding in a Construct-Dependent Manner.

bioRxiv : the preprint server for biology·2026

Same author

High-Throughput Screening Identifies Small-Molecule Inhibitors of the Tau-LRP1 Interaction.

bioRxiv : the preprint server for biology·2026

Same author

Malaria Public Health Status: Global Context and Update on Gulf Cooperation Council Countries.

Advances in experimental medicine and biology·2026

Same author

Hsp70 is phosphorylated in a conserved response to DNA damage and contributes to cell cycle control.

eLife·2026

Same author

Author Correction: High-throughput discovery of fluoroprobes that recognize amyloid fibril polymorphs.

Nature chemistry·2026

Same author

Emergence of specific binding and catalysis from a designed generalist binding protein.

Nature chemistry·2026

Search research articles

Related Experiment Video

Updated: Apr 25, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Rehabilitating mutant GCase.

Jennifer N Rauch¹, Jason E Gestwicki¹

¹Department of Pharmaceutical Chemistry, Institute for Neurodegenerative Disease, University of California at San Francisco, 675 Nelson Rising Lane, San Francisco, CA 94158, USA.

Chemistry & Biology

|August 16, 2014

Summary

This summary is machine-generated.

Gaucher's disease patients have a deficient enzyme, β-glucocerebrosidase (GCase). Researchers are exploring how GCase interacts with the proteostasis network to find new treatments beyond enzyme replacement therapy.

More Related Videos

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using In Utero Electroporation-based Gene Transfer

CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using In Utero Electroporation-based Gene Transfer

Published on: June 9, 2018

Related Experiment Videos

Last Updated: Apr 25, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using In Utero Electroporation-based Gene Transfer

CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using In Utero Electroporation-based Gene Transfer

Published on: June 9, 2018

Area of Science:

Biochemistry
Genetics
Cell Biology

Background:

Gaucher's disease is a genetic disorder caused by a deficiency of the enzyme β-glucocerebrosidase (GCase).
Current treatments primarily involve enzyme replacement therapy, which can be costly and may not address all aspects of the disease.
Understanding the cellular mechanisms underlying GCase dysfunction is crucial for developing novel therapeutic strategies.

Purpose of the Study:

To investigate the interactions between mutant β-glucocerebrosidase (GCase) and the cellular proteostasis network.
To identify potential targets within the proteostasis network for rehabilitating GCase function.
To explore alternative therapeutic approaches for Gaucher's disease beyond conventional enzyme replacement therapy.

Main Methods:

Analysis of GCase interactions with key proteostasis regulators.
Cellular assays to assess the impact of proteostasis modulation on GCase activity.
Biochemical characterization of mutant GCase behavior within the cellular environment.

Main Results:

Identification of specific components within the proteostasis network that influence GCase stability and function.
Demonstration that modulating proteostasis pathways can partially restore the activity of mutant GCase.
Insights into the molecular mechanisms by which GCase interacts with cellular quality control systems.

Conclusions:

The proteostasis network plays a significant role in the cellular fate of Gaucher's disease-associated mutant GCase.
Targeting the proteostasis network offers a promising avenue for developing novel therapeutic strategies for Gaucher's disease.
Further research into GCase-proteostasis interactions could lead to innovative treatments for lysosomal storage disorders.